Pfizer completes acquisition of Medivation

Posted on September 28, 2016 by Sitemaster

As of midnight last night, Pfizer completed the acquisition of Medivation and therefore enzalutamide (Xtandi) is now being sold in the USA by Pfizer and Astellas and by Astellas in the rest of the world. For the details, see here.

Filed under: Uncategorized | Tagged: , , , |

« »

One Response

  1. Bob Lederer, on September 28, 2016 at 4:36 pm said:

    The price is already high for enzalutamide. I suspect Pfizer will drive it higher to recover their costs of the acquisition.

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives

%d bloggers like this: